Literature DB >> 9780123

Use and abuse of the benzodiazepines.

A D Fraser1.   

Abstract

Since chlordiazepoxide was introduced in 1961, the benzodiazepines have had many important roles in the pharmacotherapy of various disorders. This drug class for the central nervous system has been considered one of the safest in use for 35 years, especially when the benzodiazepines are compared with the barbiturates they often replaced. The objective of this article is to provide an update on the availability and distribution of benzodiazepines around the world and to discuss their most common clinical applications. Adverse effects of benzodiazepines, observed after long-term therapeutic use and after overdoses, are also presented. Triazolam is discussed because this benzodiazepine was removed from the market by regulatory authorities in the United Kingdom in 1991. Benzodiazepines will continue to have an important role in clinical medicine. Their clinical use, however, should be monitored more closely because of the greater awareness of their adverse effects after long-term use and because of the potential for misuse and abuse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780123     DOI: 10.1097/00007691-199810000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Effects of diazepam on the latency of saccades for luminance and binocular disparity defined stimuli.

Authors:  Cunguo Wang; Jianliang Tong; Fuchuan Sun
Journal:  Exp Brain Res       Date:  2005-04-08       Impact factor: 1.972

Review 2.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Diazepam-induced changes of optokinetic nystagmus fast phase.

Authors:  Cunguo Wang; Jing Tian; Peiji Liang; Fuchuan Sun
Journal:  Exp Brain Res       Date:  2005-11-11       Impact factor: 1.972

Review 4.  Therapeutic potential of kava in the treatment of anxiety disorders.

Authors:  Yadhu N Singh; Nirbhay N Singh
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  The medicalization of sleeplessness: a public health concern.

Authors:  Mairead Eastin Moloney; Thomas R Konrad; Catherine R Zimmer
Journal:  Am J Public Health       Date:  2011-06-16       Impact factor: 9.308

Review 6.  Zaleplon: a review of its use in the treatment of insomnia.

Authors:  M Dooley; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

7.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Authors:  Jonathan R T Davidson; Douglas E Feltner; Ashish Dugar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

8.  The Pharmacological Assessment of GABAA Receptor Activation in Experimental Febrile Seizures in Mice.

Authors:  Yuka Kasahara; Hideyoshi Igata; Takuya Sasaki; Yuji Ikegaya; Ryuta Koyama
Journal:  eNeuro       Date:  2019-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.